Episode

E126: Risk Signals, JAKs, and SELECTIVE-ity

Podcast

The Evidence Based Rheumatology Podcast

Published

Sep 8, 2025

Duration seconds

874

Processing state

not_requested

Canonical source

https://msputman.podbean.com/e/e126-risk-signals-jaks-and-selective-ity/

Audio

https://mcdn.podbean.com/mf/web/xgd7xbymdz4swrep/e126.mp3

JSON

/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e126-risk-signals-jaks-and-selective-ity

Markdown

/podcast/the-evidence-based-rheumatology-podcast-1130175/e126-risk-signals-jaks-and-selective-ity.md

Actions

• POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e126-risk-signals-jaks-and-selective-ity/transcription-requests
  Idempotently request low-priority transcript generation for this episode.
• GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e126-risk-signals-jaks-and-selective-ity.md
  Read the agent-friendly Markdown representation of this episode resource.

Summary

Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091